RET mutations have been identified in various cancer types, including medullary thyroid cancer, papillary thyroid cancer, and lung cancer—particularly non-small cell lung cancer, where RET rearrangements account for approximately 1%–2% of cases (Thein et al., 2021; Tiurin et al., 2023). This evidence concerns the gene RET and non-small cell lung carcinoma.